Magnesium and the Cardiometabolic Syndrome

Current Nutrition Reports

Volumn 1, Issue 2, 2012, Pages 100-108

  Barbagallo, Mario ^a   Dominguez, Ligia J ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Blood pressure; Calcium; Cardiometabolic syndrome; Cardiovascular disease; Coagulation factors; Dyslipidemia; Glucose intolerance; Hypertension; Inflammation; Insulin resistance; Magnesium; Metabolic diseases; Oxidativ; Type 2 diabetes mellitus; Visceral adiposity

Indexed keywords

ADENOSINE TRIPHOSPHATE; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CYTOKINE; GLUTATHIONE TRANSFERASE; HEMOGLOBIN A1C; INSULIN; MAGNESIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ADRENERGIC SYSTEM; AGING; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MAGNESIUM DEFICIENCY; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

EID: 84887624196     PISSN: None     EISSN: 21613311     Source Type: Journal    
DOI: 10.1007/s13668-012-0010-6     Document Type: Review

References (97)

1. Barbagallo M, Dominguez LJ: Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007, 458: 40-47.
2. Saris NE, Mervaala E, Karppanen H, et al.: Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta 2000, 294: 1-26.
3. Paolisso G, Barbagallo M: Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997, 10: 346-355.
4. Barbagallo M, Gupta RK, Resnick LM: Cellular ionic effects of insulin in normal human erythrocytes: a nuclear magnetic resonance study. Diabetologia 1993, 36: 146-149.
5. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005; 365: 1415-28.
6. • Kassi E, Pervanidou P, Kaltsas G, Chrousos G.: Metabolic syndrome: definitions and controversies. BMC Medicine 2011, 9: 48. The controversies on existing definitions of metabolic syndrome are described here in addition to the need to develop uniform criteria for diagnosis.
7. Cornier MA, Dabelea D, Hernandez TL, et al: The metabolic syndrome. Endocr Rev 2008, 29: 777-822.
8. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37: 1595-1607.
9. Kahn R, Buse J, Ferrannini E, et al.: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 48: 1684-99.
10. Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009, 13: 1-7.
11. Ford ES, Li C, Zhao G: Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010, 2: 180-193.
12. McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28: 385-390.
13. Hunt KJ, Resendez RG, Williams K, et al.: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004, 110: 1251-1257.
14. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288: 2709-2716.
15. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28: 1769-1778.
16. • Mottillo S, Filion KB, Genest J, et al.: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56: 1113-1132. This a systematic review and meta-analysis of the cardiovascular risk associated with the metabolic syndrome, showing that it is associated with a twofold increase in cardiovascular outcomes and a 1. 5-fold increase in all-cause mortality.
17. Altura BM, Altura BT, Carella A: Magnesium deficiency-induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. Science 1983, 221: 376-378.
18. Altura BM, Altura BT, Gebrewold A, et al: Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 1984, 223: 1315-1317.
19. Nadler JL, Buchanan T, Natarajan R, et al.: Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993, 21: 1024-1029.
20. Joffres MR, Reed DM, Yano K: Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987, 45: 469-475.
21. Resnick LM, Gupta RK, Laragh JH: Intracellular free magnesium in erythrocytes of essential hypertension: relation to blood pressure and serum divalent cations. Proc Natl Acad Sci U S A 1984, 81: 6511-6515.
22. Resnick LM, Barbagallo M, Bardicef M, et al.: Cellular-free magnesium depletion in brain and muscle of normal and preeclamptic pregnancy: a nuclear magnetic resonance spectroscopic study. Hypertension 2004, 44: 322-326.
23. Resnick LM, Gupta RK, Bhargava KK, et al.: Cellular ions in hypertension, diabetes, and obesity. A nuclear magnetic resonance spectroscopic study. Hypertension 1991, 17: 951-957.
24. Resnick LM, Gupta RK, Gruenspan H, et al.: Hypertension and peripheral insulin resistance. Possible mediating role of intracellular free magnesium. Am J Hypertens 1990, 3: 373-379.
25. Belin RJ, He K: Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome. Magnesium Research 2007, 20: 107-129.
26. Barbagallo M, Dominguez LJ: Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am J Therapeutics 2007, 14: 375-385.
27. Barbagallo M, Gupta RK, Resnick LM: Cellular ions in NIDDM: relation of calcium to hyperglycemia and cardiac mass. Diabetes Care 1996, 19: 1393-1398.
28. Resnick LM, Militianu D, Cunnings AJ, et al.: Pulse waveform analysis of arterial compliance: relation to other techniques, age, and metabolic variables. Am J Hypertens 2000, 13: 1243-1249.
29. Shechter M, Sharir M, Labrador MJP, et al.: Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000, 102: 2353-2358.
30. • Barbagallo M, Dominguez LJ, Galioto A, et al.: Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010, 23: 131-137. The present study suggests that oral Mg improves endothelial function in diabetic older adults. Mg ions influence vascular tone and responsiveness and are cofactors for acetylcholine-induced, endothelium-dependent relaxation. Mg intervention resulted in a significant improvement in the postischemic, endothelial-dependent, flow-mediated dilation.
31. Resnick LM, Laragh JH, Sealey JE, et al.: Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983, 309: 888-891.
32. Ichihara A, Suzuki H, Saruta T: Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. J Lab Clin Med 1993, 122: 432-440.
33. Murasato Y, Harada Y, Ikeda M, et al.: Effect of magnesium deficiency on autonomic circulatory regulation in conscious rats. Hypertension 1999, 34: 247-252.
34. Blackfan K, Hamilton B: Uremia in acute glomerular nephritis: the cause and treatment in children. Med Surg J 1925, 193: 617-628.
35. Kawano Y, Matsuoka H, Takishita S, et al.: Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260-265.
36. Dyckner T, Wester PO: Effect of magnesium on blood pressure. Br Med J 1983, 286: 1847-1849.
37. Cappuccio FP, Markandu ND, Beynon GW, et al.: Lack of effect of oral magnesium on high blood pressure: a double blind study. Br Med J 1985, 291: 235-238.
38. Corica F, Corsonello A, Ientile R, et al.: Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. J Am Coll Nutr 2006, 25: 210-215.
39. Guerrero-Romero F, Rodriguez-Moran M: Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002, 39: 209-213.
40. Kao WH, Folsom AR, Nieto FJ, et al.: Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 1999, 159: 2151-2159.
41. •• Barbagallo M, Dominguez LJ: Magnesium and aging. Current Pharmaceutical Design 2010, 16: 832-839. Mg deficiency reduces the threshold antioxidant capacity of the aging organism and its resistance to free radical damage. Chronic Mg deficiency results in excessive production of oxygen-derived free radicals and low-grade inflammation, conditions common in aging and the CMetS. Mg deficits are proposed as one of the physiopathological links that may help explain the interactions among inflammation, oxidative stress with the aging process, and many age-related diseases.
42. •• Barbagallo M, Belvedere M, Dominguez LJ: Magnesium homeostasis and aging. Magnes Res 2009, 22: 235-246. Cause and mechanisms of Mg deficits with aging are described here. Chronic Mg deficiency, observed in the older adult population, has been linked to an increased risk of many preclinical and clinical outcomes, including hypertension, stroke, atherosclerosis, ischemic heart disease, cardiac arrhythmias, glucose intolerance, IR, T2DM, endothelial dysfunction, vascular remodeling, alterations in lipid metabolism, platelet aggregation/thrombosis, inflammation, oxidative stress, and cardiovascular mortality-all conditions present in the CMetS.
43. Barbagallo M, Gupta R, Dominguez LJ et al.: Cellular ionic alterations with aging: relation to hypertension and diabetes. J Am Geriatr Soc 2000, 48: 1111-1116.
44. Barbagallo M, Resnick LM, Dominguez LJ, et al.: Diabetes mellitus, hypertension and ageing: the ionic hypothesis of ageing and cardiovascular-metabolic diseases. Diabetes Metab 1997, 23: 281-294.
45. Barbagallo M, Dominguez LJ, Galioto A, et al.: Role of magnesium in insulin action, diabetes, and cardio-metabolic syndrome X. Mol Aspects Med 2003, 24: 39-52.
46. Matsunobu S, Terashima Y, Senshu T, et al.: Insulin secretion and glucose uptake in hypomagnesemic sheep fed a low magnesium, high potassium diet. J Nutr Biochem 1990, 1: 167-171.
47. Fung TT, Manson JE, Solomon CG, et al.: The association between magnesium intake and fasting insulin concentration in healthy middle-aged women. J Am Coll Nutr 2003, 22: 533-538.
48. Humphries S, Kushner H, Falkner B: Low dietary magnesium is associated with insulin resistance in a sample of young, nondiabetic black Americans. Am J Hypertens 1999, 12: 747-756.
49. Chaudhary DP, Boparai RK, Sharma R, et al.: Studies on the development of an insulin resistant rat model by chronic feeding of low magnesium high sucrose diet. Magnes Res 2004, 17: 293-300.
50. Venu L, Padmavathi IJ, Kishore YD, et al.: Long-term effects of maternal magnesium restriction on adiposity and insulin resistance in rat pups. Obesity 2008, 16: 1270-1276.
51. Suárez A, Pulido N, Casla A, et al.: Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia 1995, 38: 1262-1270.
52. Randell EW, Mathews M, Gadag V, et al.: Relationship between serum magnesium values, lipids and anthropometric risk factors. Atherosclerosis 2008, 196: 413-419.
53. Corsonello A, Perticone F, Barbagallo M, et al.: Serum magnesium and lipids: more clarity is needed. Atherosclerosis 2007; 192: 233-234.
54. Field FJ, Henning B, Mathur SN: In vitro regulation of 3-hydroxy-3-methylglutarylcoenzyme A reductase and acylcoenzyme A: cholesterol acyltransferase activities by phosphorylation-dephosphorylation in rabbit intestine. Biochim Biophys Acta 1984, 802: 9-16.
55. Rayssiguier Y, Noe L, Etienne J, et al.: Effect of magnesium deficiency on post-heparin lipase activity and tissue lipoprotein lipase in the rat. Lipids 1991, 26: 182-186.
56. Yokota K, Kato M, Lister F, et al.: Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr 2004, 23: 506S-509S.
57. Kisters K, Spieker C, Tepel M, et al.: New data about the effects of oral physiological magnesium supplementation on several cardiovascular risk factors (lipids and blood pressure). Magnes Res 1993, 6: 355-360.
58. Rasmussen HS, Aurup P, Goldstein K, et al.: Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study. Arch Intern Med 1989, 149: 1050-103.
59. Marken PA, Weart CW, Carson DS, et al.: Effects of magnesium oxide on the lipid profile of healthy volunteers. Atherosclerosis 1989, 77: 37-42.
60. Mazur A, Gueux E, Remesy C, et al.: Plasma and red blood cell magnesium concentrations in Zucker rats: influence of a high fibre diet. Magnes Res 1989, 2: 189-192.
61. Rodriguez-Hernandez H, Gonzalez JL, Rodriguez-Moran M, Guerrero-Romero F: Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res 2005, 36: 362-366.
62. Celik N, Andiran N, Yilmaz AE: The relationship between serum magnesium levels with childhood obesity and insulin resistance: a review of the literature. J Pediatr Endocrinol Metab 2011, 24: 675-678.
63. Takaya J, Higashino H, Kotera F, et al.: Intracellular magnesium of platelets in children with diabetes and obesity. Metabolism 2003, 52: 468-471.
64. Nadler JL, Malayan S, Luong H, et al.: Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992, 15: 835-841.
65. Ravn HB, Vissinger H, Kristensen SD, et al.: Magnesium inhibits platelet activity-an in vitro study. Thromb Haemost 1996, 76: 88-93.
66. Sheu JR, Hsiao G, Shen MY, et al.: Antithrombotic effects of magnesium sulfate in in vivo experiments. Int J Hematol 2003, 77: 414-419.
67. Barzilay JI, Abraham L, Heckbert SR, et al.: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50: 2384-2389.
68. Ford ES, Ajani UA, Mokdad AH: The metabolic syndrome and concentrations of C-reactive protein among U. S. youth. Diabetes Care 2005, 28: 878-881.
69. King DE, Mainous AG, Geesey ME, Woolson RF: Dietary magnesium and C-reactive protein. J Am Coll Nutr 2005, 24: 166-171.
70. Guerrero-Romero F, Rodriguez-Moran M: Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev 2006, 22: 471-476.
71. Rodriguez-Moran M, Guerrero-Romero F: Elevated concentrations of TNF-alpha are related to low serum magnesium levels in obese subjects. Magnes Res 2004, 17: 189-196.
72. Song Y, Ridker PM, Manson JE, et al.: Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U. S. women. Diabetes Care 2005, 28: 1438-1444.
73. Weglicki WB, Dickens BF, Wagner TL, et al.: Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulation T lymphocytes from magnesium-deficient mice. Magnes Res 1996, 9: 3-11.
74. Kramer JH, Mak IT, Phillips TM, et al.: Dietary magnesium intake influences circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp Biol Med 2003, 228: 665-673.
75. Malpuech-Brugere C, Nowacki W, et al.: Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta 2000, 1501: 91-98.
76. Bussiere FI, Tridon A, Zimowska W, et al.: Increase in complement component C3 is an early response to experimental magnesium deficiency in rats. Life Sci 2003, 73: 499-507.
77. Weglicki WB, Phillips TM: Pathobiology of magnesium deficiency: a cytokine /neurogenic inflammation hypothesis. Am J Physiol 1992, 263: R734-737.
78. Blache D, Devaux S, Joubert O, et al.: Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Biol Med 2006, 41: 277-284.
79. Qi L, Rimm E, Liu S, et al.: Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 2005, 28: 1022-1028.
80. Mazur A, Maier JA, Rock E, et al.: Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007, 458: 48-56.
81. Nasulewicz A, Zimowska W, Bayle D, et al.: Changes in gene expression in the lungs of Mg-deficient mice are related to an inflammatory process. Magnes Res 2004, 17: 259-263.
82. Weglicki WB, Bloom S, Cassidy MM, et al.: Antioxidant and the cardiomyopathy of Mg deficiency. Am J Cardiovasc Pathol 1992, 4: 210-216.
83. Hans CP, Chaudhary DP, Bansal DD: Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats. Magnes Res 2003, 16: 13-19.
84. Calviello G, Ricci P, Lauro L, et al.: Mg deficiency induces mineral content changes and oxidative stress in rats. Biochem Mol Biol Int 1994, 32: 903-911.
85. Touyz RM, Pu Q, He G, et al.: Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens 2002, 20: 2221-2232.
86. Barbagallo M, Dominguez LJ, Tagliamonte MR, et al.: Effect of glutathione on red blood cell intracellular magnesium: relation to glucose metabolism. Hypertension 1999, 34: 76-82.
87. Barbagallo M, Dominguez LJ, Tagliamonte MR, et al.: Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension 1999, 34: 1002-1006.
88. Lopez-Ridaura R, Willett WC, Rimm EB, et al.: Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004, 27: 134-140.
89. He K, Liu K, Daviglus ML, et al.: Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006, 113: 1675-1682.
90. Song Y, Manson JE, Buring JE, et al.: Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004, 27: 59-65.
91. • Chacko SA, Song Y, Nathan L, et al.: Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 2010, 33: 304-310. High Mg intake is associated with lower concentrations of markers of systemic inflammation and endothelial dysfunction in postmenopausal women.
92. Guerrero-Romero F, Rodriguez-Moran M: Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Arch Med Res 2005, 36: 250-257.
93. Rodriguez-Moran M, Guerrero-Romero F: Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003, 26: 1147-1152.
94. de Valk HW, Verkaaik R, van Rijn HJ, et al.: Oral magnesium supplementation in insulin-requiring type 2 diabetic patients. Diabet Med 1998, 15: 503-507.
95. Song Y, He K, Levitan EB, Manson JE, et al.: Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006, 23: 1050-1056.
96. McCarty MF: Magnesium may mediate the favorable impact of whole grains on insulin sensitivity by acting as a mild calcium antagonist. Med Hypotheses 2005, 64: 619-627.
97. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G, et al.: Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004, 30: 253-258.